Trimazosin
Title: Trimazosin
CAS Registry Number: 35795-16-5
CAS Name: 4-(4-Amino-6,7,8-trimethoxy-2-quinazolinyl)-1-piperazinecarboxylic acid 2-hydroxy-2-methylpropyl ester
Molecular Formula: C20H29N5O6
Molecular Weight: 435.47
Percent Composition: C 55.16%, H 6.71%, N 16.08%, O 22.04%
Literature References: Prepn: H. J. Hess, DE 2120495 corresp to US 3669968 (1971, 1972 both to Pfizer). Pharmacological study in rats: J. P. Buyniski et al., Clin. Exp. Hypertens. 2, 1039 (1980), C.A. 94, 76779x (1981). Cardiocirculatory effects in congestive heart failure: N. A. Awan et al., Am. J. Cardiol. 44, 126 (1979). Long-term therapeutic use: K. T. Weber et al., N. Engl. J. Med. 303, 242 (1980).
Properties: White cryst from chloroform/diisopropyl ether, mp 158-159°.
Melting point: mp 158-159°
 
Derivative Type: Hydrochloride monohydrate
CAS Registry Number: 53746-46-6
Manufacturers' Codes: CP-19106-1
Trademarks: Supres (Pfizer)
Molecular Formula: C20H29N5O6.HCl.H2O
Molecular Weight: 489.95
Percent Composition: C 49.03%, H 6.58%, N 14.29%, O 22.86%, Cl 7.24%
Properties: White cryst, mp 166-169° (dec).
Melting point: mp 166-169° (dec)
 
Therap-Cat: Antihypertensive.
Keywords: a-Adrenergic Blocker; Antihypertensive; Quinazoline Derivatives.
 
 
Status: This monograph has been retired and is no longer subject to revision or update.

Others monographs:
PyraclostrobinLead HypophosphiteProtein HydrolysatesEotaxin
DialiforTerebenePhenserineLumiracoxib
VisnaginMolybdenum HexafluorideSodium Fluorideγ-Linolenic Acid
EpratuzumabUnoprostoneTryparsamideFentonium Bromide
©2016 DrugLead US FDA&EMEA